07:00 , Oct 12, 2015 |  BC Week In Review  |  Financial News

Euroscreen completes venture financing

Euroscreen S.A. , Brussels, Belgium   Business: Proteomics   Date completed: 2015-10-02   Type: Venture financing   Raised: EUR16 million ($18 million)   Investors: SFPI-FPIM; Fund+; Vesalius Biocapital Partners; Societe Regionale d’Investissement de Wallonie S.A.;...
07:00 , Jul 27, 2015 |  BioCentury  |  Emerging Company Profile

Confo(rmation) active

Drug discovery against GPCRs can be difficult because the proteins quickly fall apart when removed from their natural membrane environment. Confo Therapeutics N.V. has developed Confobodies, which mimic the role of the G protein to...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Financial News

Confo Therapeutics completes venture financing

Confo Therapeutics N.V. , Brussels, Belgium   Business: High throughput screening, Antibodies   Date completed: 2015-06-24   Type: Venture financing   Raised: EUR3 million ($3.4 million)   Investors: Capricorn Venture Partners; Qbic Arkiv Fund; PMV...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Company News

Pronota management update

Pronota N.V. , Zwijnaarde, Belgium   Business: Diagnostic, Pharmacogenetics   Hired: Carol Greve-Philips as CBO, formerly VP of corporate development at Genzyme Corp. , which Sanofi acquired; and Els Hubloux as CFO, formerly senior investment...
07:00 , Mar 14, 2011 |  BioCentury  |  Finance

Still some pop in Benlysta

Human Genome Sciences Inc. (NASDAQ:HGSI) gained $446 million in market cap last week on the approval of Benlysta belimumab, benefitting from a better label and pricing than investors had expected. The approval was announced post-market...
07:00 , Mar 14, 2011 |  BioCentury  |  Finance

Buyside Tracks

Buyside tracks William Brooks departed Quest Management, where he was the life sciences investment director. Quest is being acquired by Capricorn Venture Partners (see BioCentury, Jan. 10)....
08:00 , Jan 10, 2011 |  BC Week In Review  |  Financial News

Capricorn Venture Partners financial update

Capricorn Venture Partners raised €42 million ($55.8 million) in a first close of its Capricorn Health-tech Fund. The fund will focus on early- to mid-stage human health technology companies in Europe. The firm is seeking...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Sign of the New Year

Sign of the New Year Capricorn Venture Partners has been busy at the turn of the new year. The firm had a first close on its new Health-tech Fund, its first dedicated life sciences fund,...
07:00 , Oct 26, 2009 |  BioCentury  |  Finance

Ebb & Flow

Despite the brutal fundraising environment, New Enterprise Associates is close to wrapping up its 13th fund. According to an SEC filing, the firm has raised $2.46 billion of a planned $2.5 billion, which would put...
08:00 , Feb 19, 2007 |  BioCentury  |  Finance

Ebb & Flow

When Invitrogen bought BioReliance for $500 million in cash in early 2004, the rationale was clear: make a bioproduction powerhouse by coupling services with products. The deal combined IVGN's media, sera, reagents, packaging and cell...